Table: Sawai Pharmaceutical -9-MTH group results (IFRS)

SAWAI group

12/02/2021 04:00

Feb 12 (Reuters)- 
              Sawai Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2020        Dec 31, 2019     Mar 31, 2021 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              142.70              140.27           200.20    
                   (+1.7 pct)          (+1.6 pct)       (+9.7 pct)  
  Operating           22.85               23.94            26.85    
                   (-4.6 pct)          (+9.3 pct)       (+0.2 pct)  
  Pretax              22.60               23.79            26.55    
                   (-5.0 pct)          (+9.0 pct)       (+0.2 pct)  
  Net                 17.39               17.32            20.05    
                   (+0.4 pct)          (+3.1 pct)       (+4.0 pct)  
  EPS Basic        397.11 yen          395.59 yen       457.85 yen  
  EPS Diluted      396.71 yen          395.27 yen                   
  Ann Div                              130.00 yen       130.00 yen  
  -Q2 Div           65.00 yen           65.00 yen                   
  -Q4 Div                               65.00 yen        65.00 yen  
 
  NOTE - Sawai Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4555.T